Exciva GmbH

Privately held: no public share price · Germany

Assets

(2 total)
2Total Assets
0Approved
0Phase 3 / Filed
2Phase 1–2 / Early
1Diseases
Showing 2 of 2 assets
Target & Modality
Phase 2/3
Serotonin 5-HT2A receptor (antagonist / inverse agonist)Small molecule
Alzheimer's Disease
Phase 2/3
NMDA receptor / 5-HT2A receptorSmall molecule
Alzheimer's Disease

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2029 (1)
January 2029 (1)
Deramciclane + DeraphanPhase 2/3Agitation Associated With Alzheimer's Disease Dementia
Est. primary completion 2029-01 · NCT07284472 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

No financial reports recorded.